Pancreatic cancer chemoresistance is driven by tumor phenotype rather than tumor genotype

Mirna Swayden, Juan Iovanna, Philippe Soubeyran*
Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, Marseille, France

* Corresponding author.
E-mail address: philippe.soubeyran@inserm.fr (P. Soubeyran).

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest forms of cancer. A major reason for this situation is the fact that these tumors are already resistant or become rapidly resistant to all conventional therapies. Like any transformation process, initiation and development of PDCA are driven by a well known panel of genetic alterations, few of them are shared with most cancers, but many mutations are specific to PDAC and are partially responsible for the great inter-tumor heterogeneity. Importantly, this knowledge has been inefficient in predicting response to anticancer therapy, or in establishing diagnosis and prognosis. Hence, the pre-existing or rapidly acquired resistance of pancreatic cancer cells to therapeutic drugs rely on other parameters and features developed by the cells and/or the micro-environment, that are independent of their genetic profiles. This review sheds light on all major phenotypic, non genetic, alterations known to play important roles in PDAC cells resistance to treatments and therapeutic escape.

Keywords: Cancer research, Oncology, Cell biology, Molecular biology
1. Introduction

Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal human malignancies with a 5-year survival rate of 7% [1]. This extremely poor prognosis is due to the lack of active screening methods able to detect the tumor at early stages. Hence, the majority of patients are diagnosed at late metastatic or advanced stages, and only 10—15% of them are able to be resected surgically [2]. With or without surgery, patients are subjected to chemotherapy where gemcitabine was the baseline treatment for more than a decade and still employed nowadays [3]. Recently, combination of gemcitabine with nab-paclitaxel [4] and Folfirinox protocol [5] were able to improve the survival rates compared to the use of gemcitabine alone. Unfortunately, PDAC has a weak response to all current treatment regimens and many clinical trials targeting specific molecular pathways failed to improve this situation (Table 1). This fact is due to the development by the tumor of an extremely efficient cellular resistance to chemotherapeutic drugs. This resistance is supported by both cellular intrinsic and extrinsic factors related to tumor microenvironment [6]. Therefore, understanding these underlying mechanisms is an essential step to increase the efficacy of treatments and to decrease the mortality rate. Some studies focused on genetic mutations to explain the phenomenon of chemo-resistance in pancreatic cancer. However accumulating evidence leads us to look beyond the genetic alterations of the tumor and to consider the existing complex level of non genetic mechanisms driving resistance. This review aims to reveal the inaccuracy of relying only on genetic mutations to explain the extreme resistance of PDAC through focusing on all non genetic mechanisms including epigenetics, post translational modifications, aberrant signaling, altered metabolism, cancer stem cells, epithelial to mesenchymal transition and the cellular and non cellular components of the tumor microenvironment (illustrated in Fig. 1).

2. Main text

2.1. Genetic mutations drive tumor progression but have a poor association with chemo-resistance

Genetic mutations in PDAC play a major role at the level of tumor initiation and development. PDAC arises from the stepwise progression of three types of precursor lesions called pancreatic intraepithelial neoplasm (PanIN), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN) [7]. These precursor lesions are classified in to low-grade or high-grade [8]. The transformation of normal tissue to neoplastic lesions and then into invasive PDAC is orchestrated by the occurrence of successive key genetic mutations. KRAS gene encodes a RAS homolog belonging to the GTPase family. The amino acid substitution from glycine to
Table 1. List of all drugs targeting specific molecular pathways which, according to Clinicaltrials.gov, were tested at least one time in clinical trials for pancreatic cancer treatment and that gave results. None of them significantly improve the standard treatments.

| Name            | Alias     | Molecular target | Pathway                  | Type      |
|-----------------|-----------|------------------|--------------------------|-----------|
| Afiblercept     | L01XX44  | VEGF             | VEGF sign                | rp        |
| Alisertib       | MLN-8237 | AURKA            | Cell cycle               | i         |
| Alvocidib       | L86-8275 | CDK9             | Cell cycle               | i         |
| Apatorsen       | OGX-427  | HSP27            | Proteostasis             | as        |
| Apricinib       | nd       | COX-2            | Multiple                 | i         |
| Axitinib        | AG-013736| VEGFR            | VEGF sign                | i         |
| Bevacizumab     | Avastin   | VEGF             | VEGF sign                | ab        |
| Bortezomib      | PS-341    | Proteasome       | Proteostasis             | i         |
| Bosutinib       | SKI-606  | BCR-ABL + SRC family | Multiple               | i         |
| Bryostatin-1    | nd       | PKC              | PKC                      | i         |
| Cabozantinib    | XL-184    | HGFR + AXL + VEGFR | Multiple               | i         |
| Cetuximab       | BMS 564717| EGFR            | EGF sign                 | ab        |
| Cixutumumab     | IMC-A12   | IGF-1R           | PI3K/AKT                 | ab        |
| Dactolisib      | BEZ235    | PI3K             | mTOR                     | i         |
| Dasatinib       | BMS-354825| BCR-ABL, SRC family, c-KIT, EPHA2, PDGFRb | Multiple | i         |
| Demcizumab      | OMP-21M18| DLL4             | Notch sign               | ab        |
| Erlotinib       | L01XE03  | EGFR             | EGF sign                 | i         |
| Etanercept      | GP-2015   | TNF α            | TNF sign                 | ab        |
| Everolimus      | RAD001   | mTORC1           | mTOR                     | i         |
| Galunisertib    | (LY2157299)| TGF-beta-R1    | TGF-beta                 | i         |
| Ganetespib      | (STA-9090)| HSP90           | Proteostasis             | i         |
| Ganitumab       | AMG 479  | IGF1-1-R         | PI3K/AKT                 | ab        |
| Imatinib        | STI571    | BCR-ABL, c-KIT, PDGFR, DDR1/2, CSF1R | Multiple | i         |
| Ipilimumab      | MDX-010  | CTLA-4           | T-Lymphocyte activation | ab        |
| Lapatinib       | gw572016 | EGFR             | EGF sign                 | i         |
| Motesanib       | AMG 706  | VEGFR            | VEGF sign                | i         |
| nd              | PF-00562271| FAK            | Adhesion/invasion        | i         |
| nd              | MK-2206  | AKT1/2/3         | PI3K/AKT                 | i         |
| nd              | RO4929097| Gamma-secretase  | Notch sign               | i         |
| Olaparib        | AZD-2281 | PARP             | DNA repair               | i         |
| Panitumumab     | ABX-EGF  | EGFR             | EGF sign                 | ab        |
| Panobinostat    | nd       | HDAC             | Multiple                 | i         |
| Pazopanib       | GW-786034| VEGFR            | VEGF sign                | i         |

(continued on next page)
aspartate in codon 12 of KRAS causes its constitutive activation observed in up to 95% of PDAC, representing the most common mutation in this cancer [9]. Oncogenic KRAS activates the MAP (Mitogen Activate Protein) kinase and the PI3 (Phosphoinositide 3) kinase pathways, leading to an increased proliferation. KRAS mutation is considered as an early event during pancreatic carcinogenesis occurring in 35% of low grade PanINs and reaching 75% in high grade PanINs [10]. This mutation facilitates the progression from low grade to high grade PanINs and is sufficient to initiate the PanIN lesions.

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) is a tumor suppressor gene encoding the P16 protein that inhibits the phosphorylation of RB (Retinoblastoma Protein) protein and blocks cell cycle progression. The loss of this function leads to entry into mitosis and an increased cell division. CDKN2A is also frequently inactivated in 95% of PDAC patients [7]. It tends to arise at late stages of PanINs, with an incidence of 30—80% in low grade PanINs, and 92% in high grade PanINs. SMAD4 (SMAD Family Member 4), a main actor of TGF-beta signaling pathway, is mutated in 55% of PDAC patients [11]. SMAD4 expression is normal in low grade PanINs but it tends to be inactivated in late stages as it is the case in 31% of high grade PanINs [11]. TP53 (Tumor Protein P53) tumor suppressor is inactivated in 75% of pancreatic cancers [7]. TP53 mutation is a late event during PanIN progression to PDAC occurring in only 12% of high grade PanINs.

### Table 1. (Continued)

| Name       | Alias  | Molecular target | Pathway                  | Type    |
|------------|--------|------------------|--------------------------|---------|
| pertuzumab | R1273  | HER2             | EGF sign                 | ab      |
| Pimasertib | AS-703026 | MEK1/2     | MAP kinase               | i       |
| Rabusertib | LY2603618 | CHK1         | Cell cycle               | i       |
| RAV12      | RAAG12 | Sodium channels (via N-linked carbohydrate antigen) | Cell homeostasis | ab      |
| Romidepsin | FK-228 | HDAC             | Multiple                 | i       |
| Ruxolitinib| INC424 | JAK1/2          | JAK-STAT                 | i       |
| Saracatinib| AZD0530| SRC family      | SRC                      | i       |
| Selumetinib| AZD6244| MEK1/2          | MAP kinase               | i       |
| Sirolimus  | Rapamycin | mTORC1/2 (via FKBP12) | mTOR                  | i       |
| Sorafenib  | BAY-43-9006 | VEGFR, PDGFR and Raf family kinases | Multiple             | i       |
| Sunitinib  | SU-011248 | RTKs          | Multiple                 | i       |
| Tanespimycin| 17-AAG     | HSP90          | Proteostasis             | i       |
| Temsirolimus| CCI-779   | mTOR           | mTOR                     | i       |
| Trametinib | GSK1120212 | MEK1/2      | MAP kinase               | i       |
| Vatalanib  | PTK787   | VEGFR, c-KIT   | Multiple                 | i       |
| Vismodegib | RG-3616  | SMO (smoothened receptor) | Hedgehog sign | i       |
| Vorinostat | MK-0683  | HDAC           | Multiple                 | i       |

ab: antibody; as: antisens; i: inhibitor, rp: recombinant protein.
Additional detailed genetic analysis of PDAC led to the identification of new important genes which are mutated at lower percentage in these tumors. These genes include RNF43 (Ring finger protein 43), ARID1A (AT-Rich Interaction Domain 1A), TGFBR2 (Transforming Growth Factor Beta Receptor2), GNAS (GNAS Complex Locus), RREB1 (Ras Responsive Element Binding Protein 1), PBRM1 (Polybromo 1), BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and CTNNB1 (Beta Catenin 1) [13]. Some of these genes could be involved in tumor progression, but this has not been demonstrated yet. A subset of these mutations, some germinal but mostly somatic, affects genes involved in DNA damage repair (DDR) which provides susceptibility to develop cancer [14]. Importantly, deficiency in DDR was also shown to increase sensitivity to PARP (Poly (ADP-ribose) polymerase) inhibitors in different cancer types [15] and recent trials in PDAC patients tend to show a relative efficacy for some of them [16, 17].

Since mutations in these specific genes are considered to be the main drivers of tumor progression, scientists attempted to exploit them as therapeutic targets. However, after several trials, it has been evident that genetic mutations could be used as targets only in a small percentage of patients, firstly because the related drugs are not available or because the mutated genes can’t be targeted by drugs. Some studies considered genetic mutations as critical component of drug resistance. A study by
Fiorini et al. proposed that TP53 mutations can drive the chemo-resistance to gemcitabine in pancreatic cancer cell lines [18]. However, a significant number of drug-resistant tumors were identified carrying no mutations in drug targets or activated pathways [19]. Several observations implied the participation of non-genetic mechanisms in drug resistance. A recent work performed in our laboratory [20] demonstrated that global genomic features (chromosomal instability index, mutation rate, copy number aberration, etc.) do not allow tumor classification or predict the response to therapy. Similar conclusions were obtained by Bailey’s and coworkers who studied a larger cohort of patients using whole-genome sequencing approach [21]. In a recent study, drug sensitivities of 28 patient-derived cell lines and xenografts towards 305 chemical agents have been tested [22]. After combining different drugs, all individual tumors could be targeted efficiently. However, in one case only there was a correlation between the treatment efficacy and the genetic mutations, where the tumors containing a mutation in STAG2 (Stromal Antigen 2) showed sensitivity to DNA cross-linking agents. Moreover, these tumors tend to be highly heterogeneous [23], composed of different cellular clones, each having different biological properties and different mutation profiles. This variety of clones often attenuates the response to treatment as the most resistant ones persist after chemotherapy and lead to relapse after a period of time [24]. Inter-tumor heterogeneity also plays an important role in response to drugs. This has been clearly demonstrated in a study where the sensitivity of five pancreatic cancer patient derived xenografts (PDXs) was tested towards MEK (Mitogen-activated protein kinase kinase) inhibitors. Despite the fact that all these PDXs carried the KRAS mutation they displayed different drug responses where two out of five PDXs were insensitive to MEK inhibitors [25]. For all these reasons, mutations solely are not reliable to explain the peculiar resistant phenotype observed in PDAC. Although a limited number of genetic mutations provoke tumor initiation and progression, the PDAC phenotype is highly heterogeneous. This suggests that this heterogeneity is engendered by genetic independent alterations, hence implying alterations at the epigenetic, transcriptomic, translational and post translational levels.

In accordance, transcriptome in PDAC was shown to be predictive of drug response and clinical outcome. A work combining laser capture micro-dissections followed by a detailed transcriptomic analysis revealed three main groups of patients named classical, quasi-mesenchymal and exocrine like, which were suggested to differ in terms of drugs sensitivities [26]. This has been confirmed by a complex computational approach on available transcriptomic data isolated from cancerous and normal gene expression profiles. This analysis led to the identification of two main tumor subtypes of which the basal like is having a poor clinical outcome [27]. Our group has studied PDAC samples from 17 patients that have been collected by endoscopic ultrasound-guided fine-needle aspiration or surgery and then xenografted in mice as PDXs and also kept as primary cultures of epithelial cells. Transcriptomic analysis
has been performed using an Affymetrix approach and, without surprise, a significant heterogeneity in the mRNA expression profiles of tumors was observed. However, the bioinformatic analysis of these data was able to discriminate between patients with long-term and short-term survival which corresponded to patients with moderately or poorly differentiated PDAC tumors respectively [28]. Primary cultures of these tumors allowed the in vitro analysis of their sensitivity to the five most relevant anticancer drugs, thereby establishing individual profiles of drug sensitivity. Importantly, the response to the treatments was patient-dependent and the transcriptomic analysis revealed a drug-specific profile of sensitivity [28]. Similarly, a positive correlation was found between resistance to FK866, a specific inhibitor for NAMPT (Nicotinamide phosphoribosyl transferase), and the expression level of NAMPT mRNA [29]. Supervised clustering analysis of these transcriptomes identified a set of genes which are over expressed or under expressed in the resistant versus sensitive cells, confirming that the transcriptome is able to determine response to treatment. A supervised clustering analysis of the transcriptome of 55 patient derived xenografts indicated the presence of two clear subgroups defined as MYC-high and MYC-low depending on the expression level of MYC dependent genes. Results of tests performed in cell culture, spheroids, organoids and xenografts showed an increased sensitivity to JQ1, an inhibitor of bromodomain family of protein (to which MYC belongs to), in the panel of cells coming from the MYC-high subgroup [30].

The combination of these facts led us to concentrate on other more relevant molecular and non genetic mechanisms that better explain this drug resistance witnessed in PDAC.

2.2. PDAC intracellular mechanisms of chemo-resistance

2.2.1. Altered metabolism

Altered metabolism contributes to the modulation of apoptosis, angiogenesis and drug targets thereby conferring a resistant phenotype [31]. Gemcitabine was and is one of the most used drugs for the treatment of PDAC patients. Evidence on the mechanisms of gemcitabine resistance has been accumulated during the last years. These mechanisms include the deficiency in ENT1 (Equilibrative Nucleoside Transporter 1) transporters, drug efflux by ABC (ATP-binding cassette) transporters, downregulation of the rate limiting enzyme deoxycytidine kinase (DCK), and the upregulation of RRM1/RRM2 (Ribonucleotide Reductase) that convert CDP (Cytidine diphosphate) to dCDP (Deoxycytidine diphosphate) [32]. Gemcitabine can also be inactivated either by deamination by cytidine deaminase or by dephosphorylation of the monophosphate form by 5’-nucleotidases [32]. Importantly, all these gemcitabine resistance mechanisms are independent of genetic alterations and are only due to altered expressions and/or activity of the involved enzymes. Other aberrations
in classical metabolic pathways such as glycolysis, oxidative phosphorylation, and fatty acids metabolism have been shown to be also involved in chemo-resistance [31].

2.2.2. Epigenetics

2.2.2.1. DNA methylation and histone acetylation

Recently, the contribution of epigenetics in resistance mechanisms of pancreatic cancer gained more attention. DNA methylation plays a central role in regulating genes transcription, and its deregulation is associated with tumorigenesis. A study by Ramachandran et al. reported that the silencing of PYCARD (PYD And CARD Domain Containing) gene, which encodes TMS1 (Target of methylation induced silencing 1), through the methylation of its promoter, is involved in resistance of pancreatic cancer [33]. Inversely, the over-expression of TMS1 via recombinant gene expression in PDAC cells or, treating these cells with the methylation inhibitor 5-azacytidine, increased their sensitivity to gemcitabine and docetaxel [33]. Histone acetylation may also contribute to pancreatic cancer cells resistance. This has been shown by Ono et al. who demonstrated that the HAT (Histone acetylase) p300 confers resistance to gemcitabine whereas its inhibition by C646 (HAT inhibitor) decreased histone acetylation and improved the sensitivity to gemcitabine [34].

2.2.2.2. MiRNAs and lncRNA

MiRNAs (micro RNAs) are double stranded RNAs of 18–24 nucleotides. They bind mRNAs (messenger RNA) to regulate their expression. Their abnormal production may contribute to resistance in cancer cells. Moriyama et al. [35] found that miR-21 is upregulated in pancreatic cancer cells and its inhibition decreased their proliferation, invasion and chemo-resistance. A comparison of miRNA profiles of gemcitabine resistant and gemcitabine sensitive pancreatic cancer cells identified 33 differentially regulated miRNAs. One of them was miR-497, which was downregulated in resistant cells, and its upregulation enhanced the sensitivity of PDAC cells to gemcitabine and erlotinib [36]. miR-33a was found to be downregulated in gemcitabine resistant cells [36] and its overexpression was able to sensitize pancreatic cancer cells to gemcitabine and inhibit tumor growth by suppressing the expression of Pim-3 kinase [37]. MiR-181b enhances the sensitivity of pancreatic cells to gemcitabine both in vitro and in vivo by downregulating BCL2 [38]. MiR-506 downregulation helps in avoiding apoptosis and induces chemo-resistance in pancreatic cancer cells through SPHK1/Akt/NF-Kb signaling pathway [39]. Both miR-211 and let-7 enhance the sensitivity to gemcitabine by downregulating RRM2 (altered metabolisms section), which is an important target of gemcitabine in pancreatic cancer cells [40].
lncRNAs are long non-coding RNA recognized as important epigenetic regulators by acting as sponges for miRNAs [41]. Some lncRNAs may be involved in PDAC such as HOTTIP (Homebox A transcript at the distal tip) which has been found upregulated in PDAC by an lncRNA microarray profiling and whose knockdown was able to sensitize PDAC cells to gemcitabine treatment [42]. Similar findings have been described regarding the lncRNA ROR (Regulator of reprogramming) whose knockdown by siRNA (Small interfering RNA) strategy could sensitize two PDAC cell lines to gemcitabine whereas its overexpression conferred resistance to gemcitabine [43].

2.2.3. Post translational modifications

When PDAC cells are subjected to chemotherapy, stress response pathways are activated. These responses are tightly regulated by specific post-translational modifications (PTMs) of involved proteins and, alterations of this system resulting in the over-activation of these stress responses can contribute substantially to resistance [44]. Looking for such alterations of PTMs in response to gemcitabine, we found that the pro-survival role of SNIP1 (Smad nuclear interacting protein 1) was enhanced upon gemcitabine treatment by a mechanism involving the activation of P38 MAP kinase which phosphorylates SNIP1 at Ser35. This phosphorylation allowed the sumoylation of SNIP1 at Lys30 which favored cell survival [45].

2.2.4. Signaling pathways

Aberrant signaling pathways are a main hallmark of tumorigenesis and drug resistance. Wnt pathway is often over-activated in PDAC and this plays an important role in drug resistance. WNT5 expression causes gemcitabine resistance in a xenograft model of PDAC [46]. Masitinib, a tyrosine kinase inhibitor, can sensitize PDAC cells to gemcitabine through the inhibition of Wnt/β-Catenin pathway [47]. Accumulating evidences also demonstrated the role of Notch pathway in chemo-resistance. NOTCH2 (Neurogenic Locus Notch Homolog Protein 2) and JAG1 (Jagged1) are upregulated in gemcitabine resistance PDAC cell lines [48], and the knock-down of NOTCH1 expression by siRNA enhanced the sensitivity of PDAC cells to gemcitabine [49]. Hedgehog pathway is also over-activated in PDAC and results in formation of a dense desmoplasia. Studies using KPC mouse model of PDAC identified the important role played by the Hedgehog pathway in resistance as the desmoplastic reaction resulted in a decreased delivery of systemic gemcitabine into the tumor [50]. NFκB (Nuclear Factor Kappa B Subunit) is another pathway constitutively activated in PDAC. The downregulation NFκB and its downstream targets such as survivin, BCL-XL (B-cell lymphoma-extra large), XIAP (X-linked inhibitor of apoptosis protein) and CIAP (Cellular inhibitor of apoptosis protein), by 3,3-diindolylmethane (DIM) was able to potentiated the efficacy of different
anti-cancer drugs in vivo and in vitro [51, 52]. The MAP kinase signaling pathway may also contribute to the chemo-resistance to certain treatments [53]. Indeed, resistant cell lines show higher ERK activity than sensitive cells and the inhibition of this pathway resulted in an increased 5-FU sensitivity, but an increased resistance to gemcitabine [53]. Finally, PI3K/AKT has been shown to be also one of the mediators of chemo-resistance to gemcitabine in pancreatic cancer, and the use of PI3K inhibitors like wortmannin and LY294002 increased the sensitivity of PDAC cells to gemcitabine [54].

2.3. Resistance’s mechanisms ruled by the tumor microenvironment

Tumor microenvironment is the interstitial tissue that surrounds cancer cells and is composed of different cell types including pancreatic stellate cells, cancer associated fibroblasts, nerve cells, endothelial cells, and inflammatory cells, in addition to extracellular matrix components. These cellular and non-cellular components can confer drug resistance through diverse actions [55].

2.3.1. Extracellular matrix (ECM)

PDAC is characterized by the overproduction of ECM components leading to fibrosis, which is mainly mediated by TGFβ signaling pathway [56]. These components interact with cancer cells resulting in the formation of a dense desmoplasia that may favor cell migration, invasion, and also chemo-resistance by preventing proper drug entrance in the tumor thereby limiting the delivery to tumor cell. Several studies demonstrated the important roles of key extracellular components like Collagens (I, III, IV), Hyaluronan, Decorin, Versican, Fibronectin, Laminin, and Osteonectin/SPARC in the process of chemo-resistance [57]. Hyaluronic acid (HA) is a glycosaminoglycan (GAG) and is a major component of the normal ECM. It was found to be increased in several tumor types, including PDAC [58], and was shown to be significantly involved in tumor progression, chemo-resistance, and poor prognosis [59]. Based on these findings, a pegylated recombinant human hyaluronidase (PEGPH20), the enzyme that breaks down HA in stroma, has been developed and demonstrated highly promising preclinical and clinical anti-tumor activity in PDAC [60].

2.3.2. Cancer stem cells (CSCs)

Like other tumor types, PDAC tumors contain cancer stem cells which are able to self-renew and to give rise to new different cell populations that form the tumor mass [61]. These pancreatic CSCs have been reported to be responsible not only for tumor recurrence but also for metastatic spread and, importantly, for chemo-
resistance of the tumor [61]. Importantly, establishment of gemcitabine-resistant pancreatic cancer cell lines showed that resistant cells were enriched in cells with CSCs markers [62].

2.3.3. Pancreatic stellate cells (PSCs)

Accumulation of reactive oxygen species (ROS), cytokines, and growth factors secreted by the tumor cells activate PSCs stimulating them to differentiate into myofibroblast phenotype secreting extracellular matrix components [63]. Factors secreted by pancreatic stellate cells produce a chemo-resistant phenotype and increase the survival of PDAC cells by preventing the H2O2-induced apoptosis and by decreasing the sensitivity of tumor cells to both gemcitabine and radiations [64]. One of these factors has been identified as Periostin which is able to increase gemcitabine resistance [65]. Pancreatic cancer cells cultured with ECM proteins produced by PSCs display an increased resistance to 5-FU, cisplatin and doxorubicin [57]. A recent study confirmed the role of PSCs in radio-resistance by activating the integrin-FAK (Focal adhesion kinase) signaling in tumor cells [66].

2.3.4. Cancer associated fibroblasts (CAFs)

CAFs represent the majority of the cellular compartment of tumor microenvironment of PDACs. A study by Richard’s et al. showed that CAFs exposed to chemotherapy play an active role in the survival and proliferation of cancer cells. They also found that CAFs are intrinsically resistant to gemcitabine. Furthermore, exposition of CAFs to gemcitabine significantly increased the release of exosomes, a type of extracellular vesicles. These exosomes tended to increase the expression of SNAIL in recipient epithelial cells, thereby promoting proliferation and drug resistance. Importantly, treatment of gemcitabine-exposed CAFs with an inhibitor of exosome release, called GW4869, significantly reduced the survival in co-cultured epithelial cells, pointing at an important role of CAFs’ exosomes in chemo-resistance [67]. Part of the mechanism by which exosomes confer chemo-resistance in pancreatic cancer cells has been revealed and involves the upregulation of two ROS detoxifying enzymes, the superoxide dismutase 2 (SOD2) and catalase (CAT), and the miR-155-mediated downregulation of gemcitabine-metabolizing enzyme, DCK [68].

2.3.5. Immune cells and inflammation

Immune cells, such as tumor associated macrophages (TAMs), can affect the response of tumor cells to chemotherapy through a process called environment-mediated drug resistance. A study by Amit et al. showed that TAMs can secrete the enzyme cytidine deaminase which metabolizes gemcitabine into its inactive form (2’,2’-difluorodeoxyuridine) thereby leading to the survival of cancerous cells and favoring the emergence of chemo-resistant clones [69]. Cytidine deaminase may
have unexpected origin as it has recently been shown that intra-tumor bacteria, mainly belonging to Gammaproteobacteria, also express and secrete a bacterial form of this enzyme which is active on gemcitabine [70]. Inflammation within the pancreatic tumor environment has been linked to chemo-resistance and tumor progression through NFκB, IL6 (interleukin 6), Toll like receptor and TGFβ pathways [71].

2.3.6. Hypoxia

PDAC is a compact solid tumor with reduced blood flow that leads to temporary or chronic hypoxia [72]. Such Hypoxic conditions stabilize HIF1α (Hypoxia inducible factor 1 alpha) which is known to participate in the resistance to chemotherapy and radiotherapy [73]. Moreover, most chemotherapies induce their toxicity also through the generation of ROS. As the generation of ROS is strongly reduced in cells under hypoxia the efficacy such treatments are also reduced [74, 75]. Hypoxia can increase the expression of P-glycoprotein, the product of multidrug resistance gene (MDR1), which is involved in drug inactivation and consequently in drug resistance [76].

2.3.7. Epithelial to mesenchymal transitions (EMT)

EMT is a process in which epithelial tumor cells lose their epithelial markers like E-cadherin and start expressing mesenchymal markers like vimentin, undergo cytoskeletal remodeling followed by loss of cell polarity and acquisition of an invasive phenotype which aids the metastatic process [77]. Recent studies suggest an important role of EMT in resistance to gemcitabine, 5-FU, and cisplatin, which can be reversed by silencing of ZEB1 (Zinc finger E-box-binding homeobox 1) in resistant PDAC cancer cell lines [78, 79].

3. Conclusion

Despite the fact that genetic mutations are responsible for the tumor development, they cannot explain the phenomenon of resistance nor help to anticipate the response to a given chemotherapeutic drug. PDAC has a well known set of mutations but, nevertheless, it displays an incredible inter-tumor and intra-tumor heterogeneity. This may explain why the past attempts to target mutations to surpass resistance and to provide more efficient cures for PDAC didn’t reach satisfactory results. Hence, it becomes obvious that other paths must be taken in order to solve the mystery of PDAC resistance and to design better treatments able to improve the survival rates. The literature contains an increasing number of examples showing that resistant mechanisms are associated with a particular phenotype of the tumor, both at the tumoral cell level and at the associated microenvironment level (Fig. 1). So, deeper investigations of these resistance mechanisms will reveal new molecular pathways.
that could be targeted either by already available molecules or by new specifically designed ones to ultimately improve the survival of PDAC patients.

**Declarations**

**Author contribution statement**

All authors listed have significantly contributed to the development and the writing of this article.

**Funding statement**

This work was supported by La Ligue Contre le Cancer, INCa, Canceropole PACA, DGOS (labellisation SIRIC) and INSERM. Mirna Swayden was supported by La Ligue Contre le Cancer and the Lebanese Ministry of the Interior and Municipalities.

**Competing interest statement**

The authors declare no conflict of interest.

**Additional information**

No additional information is available for this paper.

**References**

[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016, CA Cancer J. Clin. 66 (2016) 7–30.

[2] S. Gillen, T. Schuster, C.M. Zum Büschenfelde, H. Friess, J. Kleeff, Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages, PLoS Med. 7 (2010).

[3] F. Giuliani, M. Di Maio, G. Colucci, F. Perrone, Conventional chemotherapy of advanced pancreatic cancer, Curr. Drug Targets 13 (2012) 795–801.

[4] D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R.K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. Wei, J. Iglesias, M.F. Renschler, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N. Engl. J. Med. 369 (2013) 1691–1703.

[5] T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, Y. Becouarn, A. Adenis, J.L. Raoul, S. Gourgou-Bourgade, C. de la Fouchardiere,
J. Bennouna, J.B. Bachet, F. Khemissa-Akouz, D. Pere-Verge, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux, U. Groupe Tumeurs Digestives of, P. Intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N. Engl. J. Med. 364 (2011) 1817–1825.

[6] S. Chand, K. O’Hayer, F.F. Blanco, J.M. Winter, J.R. Brody, The landscape of pancreatic cancer therapeutic resistance mechanisms, Int. J. Biol. Sci. 12 (2016) 273–283.

[7] S. Yonezawa, M. Higashi, N. Yamada, M. Goto, Precursor lesions of pancreatic cancer, Gut Liver 2 (2008) 137–154.

[8] O. Basturk, S.M. Hong, L.D. Wood, N.V. Adsay, J. Albores-Saavedra, A.V. Biankin, L.A.A. Brosens, N. Fukushima, M. Goggins, R.H. Hruban, Y. Kato, D.S. Klimstra, G. Klöppel, A. Krasinskas, D.S. Longnecker, H. Matthaei, G.J.A. Offerhaus, M. Shimizu, K. Takaori, B. Terris, S. Yachida, I. Esposito, T. Furukawa, A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas, Am. J. Surg. Pathol. (2015) 1730–1741.

[9] G. Feldmann, R. Beaty, R.H. Hruban, A. Maitra, Molecular genetics of pancreatic intraepithelial neoplasia, J. Hepatobiliary Pancreat. Surg. 14 (2007) 224–232.

[10] B. Sipos, S. Frank, T. Gress, S. Hahn, G. Klöppel, Pancreatic intraepithelial neoplasia revisited and updated, Pancreatology 9 (2009) 45–54.

[11] C.A. Iacobuzio-Donahue, D.S. Klimstra, N.V. Adsay, R.E. Wilentz, P. Argani, T.A. Sohn, C.J. Yeo, J.L. Cameron, S.E. Kern, R.H. Hruban, Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas, Am. J. Pathol. 157 (2000) 755–761.

[12] J.B.M. Koorstra, S.R. Hustinx, G.J.A. Offerhaus, A. Maitra, Pancreatic carcinogenesis, Panreatology 8 (2008) 110–125.

[13] B.J. Raphael, R.H. Hruban, A.J. Aguirre, R.A. Moffitt, J.J. Yeh, C. Stewart, A.G. Robertson, A.D. Cherniack, M. Gupta, G. Getz, S.B. Gabriel, M. Meyerson, C. Cibulskis, S.S. Fei, T. Hinoue, H. Shen, P.W. Laird, S. Ling, Y. Lu, G.B. Mills, R. Akbani, P. Loher, E.R. Londin, I. Rigoutsos, A.G. Telonis, E.A. Gibb, A. Goldenberg, A.M. Mezlini, K.A. Hoadley, E. Colisson, E. Lander, B.A. Murray, J. Hess, M. Rosenberg, L. Bergelson, H. Zhang, J. Cho, G. Tiao, J. Kim, D. Livitz, I. Leshchiner, B. Reardon, E. Van Allen, A. Kamburov, R. Beroukhim, G. Saksena, S.E. Schumacher,
M.S. Noble, D.I. Heiman, N. Gehlenborg, J. Kim, M.S. Lawrence, V. Adsay, G. Petersen, D. Klimstra, N. Bardeesy, M.D.M. Leiserson, R. Bowlby, K. Kasaian, I. Birol, K.L. Mungall, S. Sadeghi, J.N. Weinstein, P.T. Spellman, Y. Liu, L.T. Amundadottir, J. Tepper, A.D. Singh, R. Dhir, D. Paul, T. Smyrk, L. Zhang, P. Kim, J. Bowen, J. Frick, J.M. Gastier-Foster, M. Gerken, K. Lau, K.M. Leraas, T.M. Lichtenberg, N.C. Ramirez, J. Renkel, M. Sherman, L. Wise, P. Yena, E. Zmuda, J. Shih, A. Ally, M. Balasundaram, R. Carlsen, A. Chu, E. Chuah, A. Clarke, N. Dhall, R.A. Holt, S.J.M. Jones, D. Lee, Y. Ma, M.A. Marra, M. Mayo, R.A. Moore, A.J. Mungall, J.E. Schein, P. Sipahimalani, A. Tam, N. Thiessen, K. Tse, T. Wong, D. Brooks, J.T. Auman, S. Balu, T. Bodenheimer, D.N. Hayes, A.P. Hoyle, S.R. Jefferys, C.D. Jones, S. Meng, P.A. Mieczkowski, L.E. Mose, C.M. Perou, A.H. Perou, J. Roach, Y. Shi, J.V. Simons, T. Skelly, M.G. Soloway, D. Tan, U. Veluvolu, J.S. Parker, M.D. Wilkerson, A. Korkut, Y. Senbabaoglu, P. Burch, R. McWilliams, K. Chaffee, A. Oberg, W. Zhang, M.C. Gingras, D.A. Wheeler, L. Xi, M. Albert, J. Bartlett, H. Sekhon, Y. Stephen, Z. Howard, M. Judy, A. Breggia, R.T. Shroff, S. Chudamani, J. Liu, L. Lolla, R. Naresh, T. Pihl, Q. Sun, Y. Wan, Y. Wu, S. Jennifer, K. Roggin, K.F. Becker, M. Behera, J. Bennett, L. Boice, E. Burks, C.G. Carlotti Junior, J. Chabot, D. Pretti da Cunha Tirapelli, J. Sebastião dos Santos, M. Dubina, J. Eschbacher, M. Huang, L. Huelsenbeck-Dill, R. Jenkins, A. Karpov, R. Kemp, V. Lyadov, S. Mathel, G. Manikhas, E. Montgomery, H. Noushmehr, A. Osunkoya, T. Owonikoko, O. Paklina, O. Potapova, S. Ramalingam, W.K. Rathmell, K. Rieger-Christ, C. Saller, G. Setdikova, A. Shabunin, G. Sica, T. Su, T. Sullivan, P. Swanson, K. Tarvin, M. Tavobilov, L.B. Thorne, S. Urbanski, O. Voronina, T. Wang, D. Crain, E. Curley, J. Gardner, D. Mallery, S. Morris, J. Paulauskis, R. Penny, C. Shelton, T. Shelton, K.P. Janssen, O. Bathe, N. Bahary, J. Slotta-Huspenina, A. Johns, H. Hibshoosh, R.F. Hwang, A. Sepulveda, A. Radenbaugh, S.B. Baylin, M. Berrios, M.S. Bootwalla, A. Holbrook, P.H. Lai, D.T. Maglinte, S. Mahurkar, T.J. Triche, D.J. Van Den Berg, D.J. Weisenberger, L. Chin, R. Kucherlapati, M. Kucherlapati, A. Pantazi, P. Park, G. Saksena, D. Voet, P. Lin, S. Frazier, T. Defreitas, S. Meier, L. Chin, S.Y. Kwon, Y.H. Kim, S.J. Park, S.S. Han, S.H. Kim, H. Kim, E. Furth, M. Tempoero, C. Sander, A. Biankin, D. Chang, P. Bailey, A. Gill, J. Kench, S. Grimmond, A. Johns, A.P. Cancer Genome Initiative APGI, R. Postier, R. Zuna, H. Sicotte, J.A. Demchok, M.L. Ferguson, C.M. Hutter, K.R. Mills Shaw, M. Sheth, H.J. Sofia, R. Tarnuzzer, Z. Wang, L. Yang, J. Julia Zhang, I. Felau, J.C. Zenklusen, Integrated genomic characterization of pancreatic ductal adenocarcinoma, Cancer Cell 32 (2017), 185–203.e13.
[14] N. Waddell, M. Pajic, A.M. Patch, D.K. Chang, K.S. Kassahn, P. Bailey, A.L. Johns, D. Miller, K. Nones, K. Quek, M.C.J. Quinn, A.J. Robertson, M.Z.H. Fadlullah, T.J.C. Bruxner, A.N. Christ, I. Harliwong, S. Idrisoglu, S. Manning, C. Nourse, E. Nourbakhsh, S. Wani, P.J. Wilson, E. Markham, N. Cloonan, M.J. Anderson, J.L. Fink, O. Holmes, S.H. Kazakov, C. Leonard, F. Newell, B. Poudel, S. Song, D. Taylor, N. Waddell, S. Wood, Q. Xu, J. Wu, M. Pinese, M.J. Cowley, H.C. Lee, M.D. Jones, A.M. Nagrial, J. Humphris, L.A. Chantrill, V. Chin, A.M. Steinmann, A. Mawson, E.S. Humphrey, E.K. Colvin, A. Chou, C.J. Scarlett, A.V. Pinho, M. Giry-Laterriere, I. Rooman, J.S. Samra, J.G. Kench, J.A. Pettitt, N.D. Merrett, C. Toon, K. Epari, N.Q. Nguyen, A. Barbour, N. Zeps, N.B. Jamieson, J.S. Graham, S.P. Niclou, R. Bjerkvig, R. Grützmann, D. Aust, R.H. Hruban, A. Maitra, C.A. Iacobuzio-Donahue, C.L. Wolfgang, R.A. Morgan, R.T. Lawlor, V. Corbo, C. Bassi, M. Falconi, G. Zamboni, G. Tortora, M.A. Tempero, A.J. Gill, J.R. Eshleman, C. Pilarsky, A. Scarpa, E.A. Musgrove, J.V. Pearson, A.V. Biankin, S.M. Grimmond, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature (2015).

[15] T. Helleday. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings, Mol. Oncol. (2011).

[16] E.M. O’Reilly, J.W. Lee, M.A. Lowery, M. Capanu, Z.K. Stadler, M.J. Moore, N. Dhani, H.L. Kindler, H. Estrella, H. Maynard, T. Golan, A. Segal, E.E. Salo-Mullen, K.H. Yu, A.S. Epstein, M. Segal, R. Brenner, R.K. Do, A.P. Chen, L.H. Tang, D.P. Kelsen, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma, Cancer (2018).

[17] M.A. Lowery, D.P. Kelsen, M. Capanu, S.C. Smith, J.W. Lee, Z.K. Stadler, M.J. Moore, H.L. Kindler, T. Golan, A. Segal, H. Maynard, E. Hollywood, M.E. Moynahan, E.E. Salo-Mullen, R.K.G. Do, A.P. Chen, K.H. Yu, L.H. Tang, E.M. O’Reilly, Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma, Eur. J. Cancer (2018).

[18] C. Fiorini, M. Cordani, C. Padroni, G. Blandino, S. Di Agostino, M. Donadelli, Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine, Biochim. Biophys. Acta Mol. Cell Res. 1853 (2015) 89–100.

[19] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646–674.
[20] R. Nicolle, Y. Blum, L. Marisa, C. Loncle, O. Gayet, V. Moutardier, O. Turrini, M. Giovannini, B. Bian, M. Bigonnet, M. Rubis, N. Elarouci, L. Armenoult, M. Ayadi, P. Duconseil, M. Gasmi, M. Ouaissi, A. Maignan, G. Lomberk, J.-M. Boher, J. Ewald, E. Bories, J. Garnier, A. Goncalves, F. Poizat, J.-L. Raoul, V. Secq, S. Garcia, P. Grandval, M. Barraud-Blanc, E. Norguet, M. Gilabert, J.-R. Delpero, J. Roques, E. Calvo, F. Guillaumond, S. Vasseur, R. Urrutia, A. de Reyniès, N. Dusetti, J. Iovanna, Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts, Cell Rep. 21 (2017) 2458–2470.

[21] P. Bailey, D.K. Chang, K. Nones, A.L. Johns, A.-M. Patch, M.-C. Gingras, D.K. Miller, A.N. Christ, T.J.C. Bruxner, M.C. Quinn, C. Nourse, L.C. Murtaugh, I. Harliwong, S. Idrisoglu, S. Manning, E. Nourbakhsh, S. Wani, L. Fink, O. Holmes, V. Chin, M.J. Anderson, S. Kazakoff, C. Leonard, F. Newell, N. Waddell, S. Wood, Q. Xu, P.J. Wilson, N. Cloonan, K.S. Kassahn, D. Taylor, K. Quek, A. Robertson, L. Pantano, L. Mincarelli, L.N. Sanchez, L. Evers, J. Wu, M. Pinese, M.J. Cowley, M.D. Jones, E.K. Colvin, A.M. Nagrai, E.S. Humphrey, L.A. Chantrill, A. Mawson, J. Humphris, A. Chou, M. Pajic, C.J. Scarlett, A.V. Pinho, M. Giry-Laterriere, I. Rooman, J.S. Samra, J.G. Kench, J.A. Lovell, N.D. Merrett, C.W. Toon, K. Epari, A. Robertson, L. Pantano, L. Mincarelli, L.N. Sanchez, L. Evers, J. Wu, M. Pinese, M.J. Cowley, M.D. Jones, E.K. Colvin, A.M. Nagrai, E.S. Humphrey, L.A. Chantrill, A. Mawson, J. Humphris, A. Chou, M. Pajic, C.J. Scarlett, A.V. Pinho, M. Giry-Laterriere, I. Rooman, J.S. Samra, J.G. Kench, J.A. Lovell, N.D. Merrett, C.W. Toon, K. Epari, N.Q. Nguyen, A. Barbour, N. Zeps, K. Moran-Jones, N.B. Jamieson, J.S. Graham, F. Duthie, K. Oien, J. Hair, R. Grützmann, A. Maitra, C.A. Iacobuzio-Donahue, C.L. Wolfgang, R.A. Morgan, R.T. Lawlor, V. Corbo, C. Bassi, B. Rusev, P. Capelli, R. Civitello, G. Tortora, D. Mukhopadhyay, G.M. Petersen, D.M. Munzy, W.E. Fisher, S.A. Karim, J.R. Eshleman, R.H. Hruban, C. Pilarsky, J.P. Morton, O.J. Sansom, A. Scarpa, E.A. Musgrove, U.-M.H. Bailey, O. Hofmann, R.L. Sutherland, D.A. Wheeler, A.J. Gill, R.A. Gibbs, J.V. Pearson, N. Waddell, A.V. Biankin, S.M. Grimmond, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature 531 (2016) 47–52.

[22] A.K. Witkiewicz, U. Balaji, C. Eslinger, E. McMillan, W. Conway, B. Posner, G.B. Mills, E.M. O’Reilly, E.S. Knudsen, Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer, Cell Rep. 16 (2016) 2017–2031.

[23] S. Yachida, S. Jones, I. Bozic, T. Antal, R. Leary, B. Fu, M. Kamiyama, R.H. Hruban, J.R. Eshleman, M.A. Nowak, V.E. Velculescu, K.W. Kinzler, B. Vogelstein, C.A. Iacobuzio-Donahue, Distant metastasis occurs late during the genetic evolution of pancreatic cancer, Nature 467 (2010) 1114–1117.
[24] F. Sipos, M. Constantinovits, G. Muzes, Intratumoral functional heterogeneity and chemotherapy, World J. Gastroenterol. 20 (2014) 2429–2432.

[25] K. Pedersen, F. Bilal, C. Bernadó Morales, M.T. Salcedo, T. Macarulla, D. Massó-Vallés, V. Mohan, A. Vivancos, M.-J. Carreras, X. Serres, M. Abu-Suboh, J. Balsells, E. Allende, I. Sagi, L. Soucek, J. Tabernero, J. Arribas, Pancreatic cancer heterogeneity and response to Mek inhibition, Oncogene (2017).

[26] E.A. Collisson, A. Sadanandam, P. Olson, W.J. Gibb, M. Truitt, S. Gu, J. Cooc, J. Weinke, G.E. Kim, L. Jakkula, H.S. Feiler, A.H. Ko, A.B. Olshen, K.L. Danenberg, M.A. Tempero, P.T. Spellman, D. Hanahan, J.W. Gray, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat. Med. 17 (2011) 500–503.

[27] R.A. Moffitt, R. Marayati, E.L. Flate, K.E. Volmar, S.G.H. Loeza, K.A. Hoadley, N.U. Rashid, L.A. Williams, S.C. Eaton, A.H. Chung, J.K. Smyla, J.M. Anderson, H.J. Kim, D.J. Bentrem, M.S. Talamonti, C.A. Iacobuzio-Donahue, M.A. Hollingsworth, J.J. Yeh, Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat. Genet. 47 (2015) 1168–1178.

[28] P. Duconseil, M. Gilabert, O. Gayet, C. Loncle, V. Moutardier, O. Turrini, E. Calvo, J. Ewald, M. Giovannini, M. Gasmi, E. Bories, M. Barthet, M. Ouaissi, A. Goncalves, F. Poizat, J.L. Raoul, V. Secq, S. Garcia, P. Viens, J. Iovanna, N. Dusetti, Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma, Am. J. Pathol. 185 (2015) 1022–1032.

[29] M. Barraud, J. Garnier, C. Loncle, O. Gayet, C. Lequeue, S. Vasseur, B. Bian, P. Duconseil, M. Gilabert, M. Bigonnet, A. Maignan, V. Moutardier, S. Garcia, O. Turrini, J.-R. Delpero, M. Giovannini, P. Grandval, M. Gasmi, M. Ouaissi, V. Secq, F. Poizat, N. Guibert, J. Iovanna, N. Dusetti, A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT, Oncotarget 7 (2016).

[30] B. Bian, M. Bigonnet, O. Gayet, C. Loncle, A. Maignan, M. Gilabert, V. Moutardier, S. Garcia, O. Turrini, J. Delpero, M. Giovannini, P. Grandval, M. Gasmi, M. Ouaissi, V. Secq, F. Poizat, R. Nicolle, Y. Blum, L. Marisa, M. Rubis, J. Raoul, J.E. Bradner, J. Qi, G. Lomberk, R. Urrutia, A. Saul, N. Dusetti, J. Iovanna, Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts, EMBO Mol. Med. (2017) e201606975.
[31] C. Grasso, G. Jansen, E. Giovannetti, Drug resistance in pancreatic cancer: impact of altered energy metabolism, Crit. Rev. Oncol. Hematol. 114 (2017) 139–152.

[32] Y. Jia, J. Xie, Promising molecular mechanisms responsible for gemcitabine resistance in cancer, Genes Dis. 2 (2015) 299–306.

[33] K. Ramachandran, H. Miller, E. Gordian, C. Rocha-Lima, R. Singal, Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity, Anticancer Res. 30 (2010) 3919–3925.

[34] H. Ono, M.D. Basson, H. Ito, P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer, Oncotarget 7 (2016) 51301–51310.

[35] T. Moriyama, K. Ohuchida, K. Mizumoto, J. Yu, N. Sato, T. Naba, S. Takahata, H. Toma, E. Nagai, M. Tanaka, MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance, Mol. Cancer Ther. 8 (2009) 1067–1074.

[36] J. Xu, T. Wang, Z. Cao, H. Huang, J. Li, W. Liu, S. Liu, L. You, L. Zhou, T. Zhang, Y. Zhao, MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis, Oncotarget 5 (2014) 6983–6993.

[37] C. Liang, X.-J. Yu, X.-Z. Guo, M.-H. Sun, Z. Wang, Y. Song, Q.-X. Ni, H.-Y. Li, N. Mukaida, Y.-Y. Li, MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine, Oncotarget 6 (2015) 14440–14455.

[38] B. Cai, Y. An, N. Lv, J. Chen, M. Tu, J. Sun, P. Wu, J. Wei, K. Jiang, Y. Miao, miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2, Oncol. Rep. 29 (2013) 1769–1776.

[39] J. Li, H. Wu, W. Li, L. Yin, S. Guo, X. Xu, Y. Ouyang, Z. Zhao, S. Liu, Y. Tian, Z. Tian, J. Ju, B. Ni, H. Wang, Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling, Oncogene 35 (2016) 5501–5514.

[40] M. Maftouh, A. Avan, N. Funel, A.E. Frampton, H. Fuji, S. Pelliccioni, L. Castellano, V. Galla, G.J. Peters, E. Giovanni, MiR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells, Nucleosides, Nucleot. Nucleic Acids 33 (2014) 384–393.
[41] M. Migault, E. Donnou-Fournet, M.D. Galibert, D. Gilot, Definition and identification of small RNA sponges: focus on miRNA sequestration, Methods (2016).

[42] Z. Li, X. Zhao, Y. Zhou, Y. Liu, Q. Zhou, H. Ye, Y. Wang, J. Zeng, Y. Song, W. Gao, S. Zheng, B. Zhuang, H. Chen, W. Li, H. Li, H. Li, Z. Fu, R. Chen, The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer, J. Transl. Med. 13 (2015) 442.

[43] C. Li, Z. Zhao, Z. Zhou, R. Liu, Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis, Cancer Chemother. Pharmacol. 78 (2016) 1199–1207.

[44] E. Tiligada, Chemotherapy: induction of stress responses, Endocr. Relat. Cancer (2006).

[45] T. Bonacci, S. Audebert, L. Camoin, E. Baudelet, G. Bidaud, M. Garcia, I.I. Witzel, N.D. Perkins, J.P. Borg, J.L. Iovanna, P. Soubeyran, Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins, J. Proteome Res. 13 (2014) 2478–2494.

[46] H. Griesmann, S. Ripka, M. Pralle, V. Ellenrieder, S. Baumgart, M. Buchholz, C. Pilarsky, D. Aust, T.M. Gress, P. Michl, WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer, Neoplasia 15 (2013) 11–22.

[47] M. Humbert, N. Castéran, S. Letard, K. Hanssens, J. Iovanna, P. Finetti, F. Bertucci, T. Bader, C.D. Mansfield, A. Moussy, O. Hermine, P. Dubreuil, Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model, PLoS One 5 (2010).

[48] Z. Wang, Y. Li, D. Kong, S. Banerjee, A. Ahmad, A.S. Azmi, S. Ali, J.L. Abbrezese, G.E. Gallick, F.H. Sarkar, Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway, Cancer Res. 69 (2009) 2400–2407.

[49] C. Güngör, H. Zander, K.E. Effenberger, Y.K. Vashist, T. Kalinina, J.R. Ibicki, E. Yekebas, M. Bockhorn, Notch signaling activated by replication stress-induced expression of Midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer, Cancer Res. 71 (2011) 5009–5019.
[50] K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, K.K. Frese, G. Denicola, C. Feig, C. Combs, S.P. Winter, H. Ireland-Zechini, S. Reichelt, W.J. Howat, A. Chang, M. Dhara, L. Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S.R. Hingorani, P. Huang, S.E. Davies, W. Plunkett, M. Egorin, R.H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, D.A. Tuveson, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science 324 (2009) 1457–1461.

[51] S. Banerjee, Z. Wang, D. Kong, F.H. Sarkar, 3,3'-diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer, Cancer Res. 69 (2009) 5592–5600.

[52] A.C. Bharti, B.B. Aggarwal, Nuclear factor-kappa B and cancer: its role in prevention and therapy, Biochem. Pharmacol. 64 (2002) 883–888.

[53] Y. Zhao, S. Shen, J. Guo, H. Chen, D. Yu Greenblatt, J. Kleeff, Q. Liao, G. Chen, H. Friess, P. Sing Leung, Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells, J. Surg. Res. 136 (2006) 325–335.

[54] S.S.W. Ng, M.S. Tsao, S. Chow, D.W. Hedley, Inhibition of phosphatidylinositol 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells, Cancer Res. 60 (2000) 5451–5455.

[55] M. Schober, R. Jesenofsky, R. Faissner, C. Weidenauer, W. Hagmann, P. Michl, R.L. Heuchel, S.L. Haas, J.M. Löhrl, Desmoplasia and chemoresistance in pancreatic cancer, Cancers (Basel) 6 (2014) 2137–2154.

[56] R. Raghow, Role of transforming growth factor-β in repair and fibrosis, Chest (1991).

[57] H. Miyamoto, T. Murakami, K. Tsuchida, H. Sugino, H. Miyake, S. Tashiro, Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins, Pancreas 28 (2004) 38–44.

[58] A. Kultti, X. Li, P. Jiang, C.B. Thompson, G.I. Frost, H. Michael Shepard, Therapeutic targeting of hyaluronan in the tumor stroma, Cancers (Basel) (2012).

[59] C.J. Whatcott, C.H. Diep, P. Jiang, A. Watanabe, J. Lobello, C. Sima, G. Hostetter, H.M. Shepard, D.D. Von Hoff, H. Han, Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer, Clin. Cancer Res. (2015).
[60] S.R. Hingorani, W.P. Harris, J.T. Beck, B.A. Berdov, S.A. Wagner, E.M. Pshevlotsky, S.A. Tjulandin, O.A. Gladkov, R.F. Holcombe, R. Korn, N. Raghunand, S. Dychter, P. Jiang, H.M. Shepard, C.E. Devoe, Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer, Clin. Cancer Res. (2016).

[61] P.C. Hermann, S.L. Huber, T. Herrler, A. Aicher, J.W. Ellwart, M. Guba, C.J. Bruns, C. Heeschen, Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer, Cell Stem Cell 1 (2007) 313–323.

[62] Z. Du, R. Qin, C. Wei, M. Wang, C. Shi, R. Tian, C. Peng, Pancreatic cancer cells resistant to chemoradiotherapy rich in “Stem-Cell-Like” tumor cells, Dig. Dis. Sci. 56 (2011) 741–750.

[63] M.V. Apte, J.S. Wilson, A. Lugea, S.J. Pandol, A starring role for stellate cells in the pancreatic cancer microenvironment, Gastroenterology 144 (2013) 1210–1219.

[64] J.A.G. Moir, J. Mann, S.A. White, The role of pancreatic stellate cells in pancreatic cancer, Surg. Oncol. 24 (2015) 232–238.

[65] Y. Liu, F. Li, F. Gao, L. Xing, P. Qin, X. Liang, J. Zhang, X. Qiao, L. Lin, Q. Zhao, L. Du, Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer, Tumor Biol. 37 (2016) 15283–15291.

[66] T.S. Mantoni, S. Lunardi, O. Al-Assar, A. Masamune, T.B. Brunner, Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling, Cancer Res. 71 (2011) 3453–3458.

[67] K.E. Richards, A.E. Zeleniak, M.L. Fishel, J. Wu, L.E. Littlepage, R. Hill, Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells, Oncogene 36 (2017) 1770–1778.

[68] G.K. Patel, M.A. Khan, A. Bhardwaj, S.K. Srivastava, H. Zubair, M.C. Patton, S. Singh, M. Khushman, A.P. Singh, Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK, Br. J. Cancer (2017).

[69] M. Amit, Z. Gil, Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase, Oncoimmunology 2 (2013) e27231.

[70] L.T. Geller, M. Barzily-Rokni, T. Danino, O.H. Jonas, N. Shental, D. Nejman, N. Gavert, Y. Zwang, Z.A. Cooper, K. Shee, C.A. Thaiss, A. Reuben,
J. Livny, R. Avraham, D.T. Frederick, M. Ligorio, K. Chatman, S.E. Johnston, C.M. Mosher, A. Brandis, G. Fuks, C. Gurbatri, V. Gopalakrishnan, M. Kim, M.W. Hurd, M. Katz, J. Fleming, A. Maitra, D.A. Smith, M. Skalak, J. Bu, M. Michaud, S.A. Trauger, I. Barshack, T. Golan, J. Sandbank, K.T. Flaherty, A. Mandinova, W.S. Garrett, S.P. Thayer, C.R. Ferrone, C. Huttenhower, S.N. Bhatia, D. Gevers, J.A. Wargo, T.R. Golub, R. Straussman, Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine, Science (80-) 357 (2017) 1156–1160.

[71] S. Hausmann, B. Kong, C. Michalski, M. Erkan, H. Friess, The role of inflammation in pancreatic cancer, Adv. Exp. Med. Biol. 816 (2014) 129–151.

[72] P. Vaupel, A. Mayer, Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications, Adv. Exp. Med. Biol. 812 (2014) 19–24.

[73] R.G. Bristow, R.P. Hill, Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability, Nat. Rev. Cancer 8 (2008) 180–192.

[74] H. Zhang, P. Gao, R. Fukuda, G. Kumar, B. Krishnamachary, K.I. Zeller, C.V. Dang, G.L. Semenza, HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity, Cancer Cell 11 (2007) 407–420.

[75] J.P. Fruehauf, F.L. Meyskens, Reactive oxygen species: a breath of life or death? Clin. Cancer Res. 13 (2007) 789–794.

[76] K.M. Comerford, T.J. Wallace, J. Karhausen, N.A. Louis, M.C. Montalto, S.P. Colgan, Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene, Cancer Res. 62 (2002) 3387–3394.

[77] J.J. Christiansen, A.K. Rajasekaran, Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis, Cancer Res. 66 (2006) 8319–8326.

[78] T. Arumugam, V. Ramachandran, K.F. Fournier, H. Wang, L. Marquis, J.L. Abbruzzese, G.E. Gallick, C.D. Logsdon, D.J. McConkey, W. Choi, Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer, Cancer Res. 69 (2009) 5820–5828.

[79] U. Wellner, T. Brabletz, T. Keck, ZEB1 in pancreatic cancer, Cancers (Basel) 2 (2010) 1617–1628.